Several humanized and fully human anti-NGF monoclonal antibodies have entered clinical trials as potential analgesics, with preliminary results showing significant improvement in chronic pain from osteoarthritis [10] and diabetic peripheral neuropathy [11, 12] and mixed results for relief of chronic low back pain [13]. Here, NGF is linked to osteoarthritis.